← Leaderboards
Tim Platts-Mills
Ophirex, Inc.
$963,552
Attributed
$2,890,656
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
FDA$2,890,656 · 1
By mechanism
R01$2,890,656 · 1
Top collaborators
- Rebecca Wonder Carter3 shared
- Matthew Robert Lewin3 shared
Grant awards (3)
Development of Intravenous Varespladib, a Phospholipase A2 Inhibitor, for the Treatment of Snakebite Envenoming$1,109,888
R01 · FY2025 · FD · contact PI
Development of Intravenous Varespladib, a Phospholipase A2 Inhibitor, for the Treatment of Snakebite Envenoming$886,309
R01 · FY2024 · FD · contact PI
Development of Intravenous Varespladib, a Phospholipase A2 Inhibitor, for the Treatment of Snakebite Envenoming$894,459
R01 · FY2023 · FD · contact PI